Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Idiopathic Pulmonary Fibrosis | Research

Changes in physical activity in people with idiopathic pulmonary fibrosis before and after virtual pulmonary rehabilitation: a feasibility study

Authors: Orlagh O’Shea, Grainne Murphy, Lynn Fox, Katherine M.A. O’Reilly

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background

Pulmonary rehabilitation (PR) is recommended for the treatment of people with idiopathic pulmonary fibrosis (IPF). Physical activity is an important health behaviour, closely linked to survival in people with IPF. Little is known about the impact of virtual (V) PR on physical activity in people with IPF.

Objective

To explore the feasibility of conducting a trial to explore effect of virtual PR on objectively measured physical activity in people with IPF.

Methods

All patients with a diagnosis of IPF in a stable phase of the disease were invited to participate in VPR: a 10 week exercise programme delivered twice-weekly for one hour. Data were collected at baseline (BL) and post VPR (10 weeks): Kings Brief Interstitial Lung Disease (K-BILD), Exercise capacity (6-minute walk test (6MWT) or 1-minute sit-to-stand (STS)) and Physical Activity. Physical activity was measured with a triaxial accelerometer for seven days. Screening, recruitment, adherence and safety data were collected.

Results

68 people were screened for this study. N = 16 participants were recruited to the study. There was one dropout. N = 15 completed VPR. All results reported in mean (standard deviation) (SD). Participants attended 18.1(2.0) of the 20 sessions. No adverse events were detected. The mean age of participants was 71.5(11.5) years, range: 47–95 years; 7 M:9 F. Mean (SD) FEV1 2.3(0.3)L, FVC 2.8(0.7)L. No statistically significant changes were observed in outcome measures apart from exercise capacity. Light physical activity increased from 152(69.4) minutes per day (n = 16) to 161.9(88.7) minutes per day (n = 14), mean change (SD) (CI) p-value: 9.9 (39.8) [-12.3 to 30.9] p = 0.4. Moderate-to-vigorous physical activity increased from 19.1(18.6) minutes per day (n = 16) to 25.7(28.3) minutes per day (n = 14), mean change (SD) (CI) p-value: 6.7 (15.5) [-2.1 to 15.1] p = 0.1. Step count increased from 3838(2847) steps per day (n = 16) to 4537(3748) steps per day (n = 14), mean change (SD) (CI) p-value: 738 (1916) [-419.3 to 1734.6] p = 0.2. K-BILD (n = 15) increased from 55.1(7.4) at BL to 55.7(7.9) post VPR mean change (SD) [95% confidence interval] (CI) p-value: 1.7(6.5) [-1.7 to 5.3], p = 0.3. 6MWT (n = 5) increased from 361.5(127.1) to 452.2(136.1) meters, mean change (SD) (CI) p-value: 63.7 (48.2) [-3.8 to 123.6], p = 0.04 and 1-minute STS increased from 17.6(3.0) (n = 11) to 23.7(6.3) (n = 10), mean change (SD) (CI) p-value 5.8 (4.6) [2.6 to 9.1], p = 0.003.

Conclusion

VPR can improve physical activity in people with IPF. A number of important feasibility issues included recruitment, retention, adherence and safety have been reported which are crucial for future research in this area. A fully powered trial is needed to determine the response of people with IPF to PR with regard to physical activity.
Appendix
Available only for authorised users
Literature
2.
go back to reference American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304. https://doi.org/10.1164/ajrccm.165.2.ats01.CrossRef American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304. https://​doi.​org/​10.​1164/​ajrccm.​165.​2.​ats01.CrossRef
3.
go back to reference Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.CrossRefPubMedPubMedCentral
4.
go back to reference Wallaert B, Monge E, Le Rouzic O, Wemeau-Stervinou L, Salleron J, Grosbois JM. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest. 2013;144:1652–8. [CrossRef] [PubMed].CrossRefPubMed Wallaert B, Monge E, Le Rouzic O, Wemeau-Stervinou L, Salleron J, Grosbois JM. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest. 2013;144:1652–8. [CrossRef] [PubMed].CrossRefPubMed
8.
go back to reference Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.CrossRefPubMed Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.CrossRefPubMed
10.
go back to reference Cox NS, Dal Corso S, Hansen H. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Reviews 2021, Issue 1. Cox NS, Dal Corso S, Hansen H. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Reviews 2021, Issue 1.
11.
22.
go back to reference Holland AE, Malaguti C, Hoffman M, Lahham A, Burge AT, Dowman L, May AK, Bondarenko J, Graco M, Tikellis G, Lee JY, Cox NS. Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: a rapid review. Chronic Resp Dis. 2020;17:1479973120952418. https://doi.org/10.1177/1479973120952418.CrossRef Holland AE, Malaguti C, Hoffman M, Lahham A, Burge AT, Dowman L, May AK, Bondarenko J, Graco M, Tikellis G, Lee JY, Cox NS. Home-based or remote exercise testing in chronic respiratory disease, during the COVID-19 pandemic and beyond: a rapid review. Chronic Resp Dis. 2020;17:1479973120952418. https://​doi.​org/​10.​1177/​1479973120952418​.CrossRef
23.
go back to reference Oishi K, Matsunaga K, Asami-Noyama M, Yamamoto T, Hisamoto Y, Fujii T, Harada M, Suizu J, Murakawa K, Chikumoto A, Matsuda K, Kanesada H, Kikuchi Y, Hamada K, Uehara S, Suetake R, Ohata S, Murata Y, Yamaji Y, Sakamoto Y, Yano M. The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease. NPJ Prim care Respiratory Med. 2022;32(1):5. https://doi.org/10.1038/s41533-022-00268-w.CrossRef Oishi K, Matsunaga K, Asami-Noyama M, Yamamoto T, Hisamoto Y, Fujii T, Harada M, Suizu J, Murakawa K, Chikumoto A, Matsuda K, Kanesada H, Kikuchi Y, Hamada K, Uehara S, Suetake R, Ohata S, Murata Y, Yamaji Y, Sakamoto Y, Yano M. The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease. NPJ Prim care Respiratory Med. 2022;32(1):5. https://​doi.​org/​10.​1038/​s41533-022-00268-w.CrossRef
26.
go back to reference Nolan CM, Patel S, Barker RE, et al. Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open. 2021;11:e048808.CrossRefPubMedPubMedCentral Nolan CM, Patel S, Barker RE, et al. Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open. 2021;11:e048808.CrossRefPubMedPubMedCentral
30.
go back to reference Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Frankenberger M, Neurohr C, Prasse A, Freise J, Behr J, Hitzl W, Koczulla AR, Kenn K. Short-term effects of Comprehensive Pulmonary Rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a Randomized Controlled Trial. J Clin Med. 2020;9(5):1567. https://doi.org/10.3390/jcm9051567.CrossRefPubMedPubMedCentral Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Frankenberger M, Neurohr C, Prasse A, Freise J, Behr J, Hitzl W, Koczulla AR, Kenn K. Short-term effects of Comprehensive Pulmonary Rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a Randomized Controlled Trial. J Clin Med. 2020;9(5):1567. https://​doi.​org/​10.​3390/​jcm9051567.CrossRefPubMedPubMedCentral
Metadata
Title
Changes in physical activity in people with idiopathic pulmonary fibrosis before and after virtual pulmonary rehabilitation: a feasibility study
Authors
Orlagh O’Shea
Grainne Murphy
Lynn Fox
Katherine M.A. O’Reilly
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-03030-9

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.